EMD 640744

Drug Profile

EMD 640744

Alternative Names: DPX-Survivac; EMD640744; Survivac

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer IMV; Merck Serono; Sunnybrook Health Sciences Centre; University of Rome
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Fallopian tube cancer; Glioblastoma; Ovarian cancer; Peritoneal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 06 Jun 2018 Positive safety, efficacy and pharmacodynamics data from phase Ib/II trial in Ovarian cancer released by IMV
  • 03 May 2018 Immunovaccine is now called IMV
  • 24 Apr 2018 Immunovaccine and Incyte plan a phase II trial for Ovarian cancer (Combination therapy, Late-stage disease, Recurrent)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top